secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001193125-26-208958
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Aptevo Reports 87% Clinical Benefit Rate and 81% Remission in Frontline AML Trial RAINIER
--------------------------------------------------------------------------------

- Across 31 evaluable frontline AML patients, mipletamig combo showed 87% clinical benefit rate and 81% remission (CR/CRi), outperforming VIALE-A benchmark of 66.4%.
- Phase 1b dose optimization trial on track for 2026 completion; final cohorts 6 and 7 under enrollment with Cohort 6 nearing completion.
- 65% achieved complete remission vs 37% historical benchmark; 52% of remissions were MRD-negative.
- No cytokine release syndrome reported; 6 patients proceeded to allogeneic stem cell transplant.
- Phase 2 dose selection and regulatory interaction planned after dataset completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526208958/0001193125-26-208958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526208958/apvo-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-208958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer